Annual Meeting, held on 7-10 December, early results from the double-blind, randomised, placebo-controlled, Phase III inMIND clinical trial were presented.

Lisata Therapeutics has completed the enrolment of subjects for the CENDIFOX study of certepetide across multiple cancer types.

Daiichi Sankyo has announced the dosage of the first subject in the trial of VANFLYTA in adults with newly diagnosed FLT3-ITD negative AML.

Creating contingency plans against geopolitical uncertainty was a key theme at the 2024 Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.

The results from the Phase III trial found the LDL-C treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.

The Phase I trial of the company’s SRSD107 siRNA therapy found the treatment to be safe and well tolerated in its first-in-human tests.

Vivoryon's VIVA-MIND trial echoed the disappointing AD findings of its VIVIAD trial but offers promise in treating kidney function.

Enanta Pharmaceuticals has reported positive topline outcomes from a Phase II trial of zelicapavir for RSV in paediatric patients.

While treatments for chronic hand eczema are available, there is significant unmet need in long-term disease management and symptom control.

AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon for early-stage Parkinson's disease met its primary endpoint.

US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ovarian cancer.

BioAge Labs has halted the Phase II randomised STRIDES trial of azelaprag,following the observation of liver transaminitis in some patients.